Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Group 1 - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation programmed T cell therapies for cancer and autoimmune diseases [3] - The company will present updated findings from the CARLYSLE study at the American College of Rheumatology Convergence 2025, highlighting its ongoing research in severe refractory systemic lupus erythematosus (srSLE) [1][2] - The CARLYSLE study's preliminary results indicate a manageable safety profile for the CD19-targeting CAR T therapy, with no dose limiting toxicities, ICANS, or Grade ≥2 CRS observed [2] Group 2 - Autolus utilizes proprietary T cell programming technologies to create targeted therapies that can effectively recognize and eliminate target cells [3] - The company has a marketed therapy, AUCATZYL, and is developing a pipeline of candidates for hematological malignancies, solid tumors, and autoimmune diseases [3]